30GX
Structure of recombinant human BChE in complex with 1-benzylpyrrolidin-3-yl o-tolylcarbamate
This is a non-PDB format compatible entry.
Summary for 30GX
| Entry DOI | 10.2210/pdb30gx/pdb |
| Descriptor | Cholinesterase, alpha-L-fucopyranose-(1-6)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (9 entities in total) |
| Functional Keywords | butyrylcholinesterase, inhibitor, complex, hydrolase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 1 |
| Total formula weight | 63607.19 |
| Authors | Brazzolotto, X.,Mastnak-Sokolov, P.,Kozak, U.,Gobec, S.,Nachon, F. (deposition date: 2026-04-24, release date: 2026-10-07, Last modification date: 2026-11-04) |
| Primary citation | Mastnak-Sokolov, P.,Kosak, U.,Meden, A.,Knez, D.,Zakelj, S.,Horvat, S.,Pislar, A.,Kljun, J.,Igert, A.,Dias, J.,Nachon, F.,Brazzolotto, X.,Novak, M.,Rydlova, V.,Karasova, J.Z.,Soukup, O.,Manik, A.,Detka, J.,Salat, K.,Gobec, S. Structure-Guided Design of a Brain-Penetrant Covalent Inhibitor of Human Butyrylcholinesterase with In Vivo Procognitive Efficacy. J.Med.Chem., 69:22506-22538, 2026 Cited by PubMed Abstract: Butyrylcholinesterase (BChE) has emerged as a validated therapeutic target for the management of Alzheimer's disease symptoms, particularly in advanced stages when acetylcholinesterase activity declines. Despite the numerous BChE inhibitors reported, only the cymserine derivative bisnorcymserine has progressed to clinical evaluation. Here, we report the design and characterization of a novel selective human BChE (hBChE) inhibitor, N-benzylpyrrolidine carbamate (S)-(+)-14. Kinetic analyses and X-ray crystallography of the hBChE-inhibitor complex confirm a covalent mechanism of inhibition. Compound (S)-(+)-14 demonstrates favorable metabolic stability and achieves brain exposure following intraperitoneal administration in mice. In a scopolamine-induced cognitive impairment model, (S)-(+)-14 improves cognitive performance without causing cholinergic adverse effects or motor deficits. Collectively, these findings identify (S)-(+)-14 as a structurally validated, brain-penetrant covalent hBChE inhibitor and highlight its promise as a lead compound for the treatment of Alzheimer's disease. PubMed: 42917927DOI: 10.1021/acs.jmedchem.6c01737 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.5 Å) |
Structure validation
Download full validation report






